Biliary Atresia Treatment Market 2023 Outlook, Growth, Trends and Forecast to 2030

 

The global Biliary Atresia Treatment Market is estimated to be valued at US$ 1,064.2 Mn in 2023 and is expected to exhibit a CAGR of 8.1% over the forecast period 2027 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Biliary atresia is a rare disease in infants that causes progressive destruction of the bile ducts within or outside the liver, resulting in cholestasis and progressive liver disease. The standard treatment for biliary atresia is the Kasai portoenterostomy surgery to reconnect the bile ducts. However, gene therapies aiming to cure the underlying cause are emerging as a promising alternative treatment approach.

Market key trends:
One of the major trends gaining traction in the market is increasing research and development of gene therapies for the treatment of biliary atresia. Gene therapies offer the potential to cure the disease by correcting the genetic abnormalities underlying biliary atresia. Some of the gene therapies under investigation target genetically modifiable mechanisms like cystic fibrosis transmembrane conductance regulator (CFTR) function. Positive results from ongoing clinical trials evaluating the safety and efficacy of gene therapies could significantly boost their adoption over the forecast period.

Segment Analysis
The global biliary atresia treatment market is segmented based on treatment type, end user, and region. Based on treatment type, the market is segmented into medication, surgery, and liver transplant. The surgery segment dominates the market as it is the most effective and permanent treatment option for biliary atresia. Kasai portoenterostomy is the most commonly performed surgical procedure to restore bile duct flow in children diagnosed with biliary atresia.

Key Takeaways
Market size: The global biliary atresia treatment market is expected to witness high growth, exhibiting CAGR of 8.1% over the forecast period, due to increasing prevalence of biliary atresia, rising healthcare expenditure, and growing awareness regarding treatment options.
Regional analysis: North America dominates the global market owing to high healthcare spending and availability of advanced treatment options in the region. The Asia Pacific region is expected to grow at the fastest rate during the forecast period due to increasing cases of biliary atresia, rising healthcare expenditure, and improving healthcare infrastructure in emerging economies.

Key players: Key players operating in the biliary atresia treatment market are AstraZeneca plc, Eisai Co., Ltd., Mirum Pharmaceuticals, Inc., Pfizer Inc., Albireo Pharma, Inc., Novartis AG, Alkem Labs, and Glenmark Pharmaceuticals. Eisai Co., Ltd. and Pfizer Inc. dominate the market due to their extensive portfolio of treatment options and global commercial presence.

Wilson’s Disease Treatment Market Breaking The Ground With Top Players

 

The global Wilson’s Disease Treatment Market is estimated to be valued at US$ 560.2 Mn or Mn in 2023 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview: 

Wilson's disease is a rare inherited disorder in which copper builds up in the body. It primarily affects the liver and brain. The disease develops due to faulty copper transport, leading to excess copper accumulation. Common treatments for Wilson's disease include chelating agents, which bind and remove excess copper from the body.

Market key trends:

One of the key trends in the Wilson's disease treatment market is the rising adoption of artificial intelligence in disease diagnosis and management. AI tools are being used to analyze various diagnostic parameters such as medical history, symptoms, laboratory test results etc. to accurately diagnose Wilson's disease at an early stage. This is significantly improving disease management and outcomes. AI aids in developing personalized treatment plans, predicting disease progression, and monitoring treatment response in patients.
Segment Analysis

The global Wilson's disease treatment market can be segmented based on treatment type and region. Based on treatment type, the market is segmented into copper removal therapies and supportive therapies. Copper removal therapies hold the dominant market share owing to their effectiveness in treating Wilson's disease. Medications such as D-penicillamine and trientine are used for copper removal and account for over 60% of the total market.

Key Takeaways

Market size
The global Wilson's disease treatment market is expected to witness high growth, exhibiting a CAGR of 6.3% over the forecast period, due to increasing prevalence of Wilson's disease. As per estimates, around 1 in 30,000 people worldwide suffer from Wilson's disease.

Regional analysis
North America holds the dominant share in the global Wilson's disease treatment market owing to the high treatment rate and increasing healthcare expenditure. Europe is the second largest market for Wilson's disease treatment. However, Asia Pacific is expected to witness the highest growth rate over the forecast period owing to improving healthcare infrastructure and increasing awareness about Wilson's disease.

Key players
Key players operating in the Wilson’s disease treatment market are Valeant Pharmaceuticals International, Inc., Noblepharma Co., Ltd., Wilson Therapeutics AB, Kadmon Holdings, Inc., Merck & Co., Inc., VHB Life Science Ltd., Teva Pharmaceuticals USA, Inc., and Tsumura & Co. Merck & Co. and Teva Pharmaceuticals USA, Inc. hold the major market share as they offer effective generic medications for Wilson's disease.

Vitamin and Mineral Supplement Tablets Market Size, Trends, Industry Analysis, Overview, Share And Forecast 2023 To 2030

 

The global Vitamin and Mineral Supplement Market is estimated to be valued at US$ 15.46 Bn in 2023 and is expected to exhibit a CAGR of 4.7% over the forecast period 2028 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Vitamin and mineral supplement tablets provide essential vitamins and minerals needed by the body. They are increasingly being consumed by health-conscious individuals to supplement their diets and meet daily nutritional requirements.

Market key trends:
The growth of the vitamin and mineral supplement tablets market is driven by rising awareness about maintaining good health and wellness. One of the key trends is the emergence of customized or personalized vitamin supplements which are tailored as per an individual's specific nutrient deficiency or health condition. Brands are designing supplements focused on single or multiple vitamin and mineral deficiencies to better target consumer needs. This is allowing people to meet their nutritional gaps in a focussed manner.
Segment Analysis
The global vitamin and mineral supplement tablets market is segmented into vitamin tablets and mineral tablets. The vitamin tablets segment dominates the market owing to increasing incidence of vitamin deficiency disorders globally. Within the vitamin tablets segment, multivitamin tablets command the largest market share. Factors such as increasing health consciousness amongst consumers and busy lifestyles resulting in poor dietary plans have increased the demand for multivitamin supplements.

Key Takeaways
The global vitamin and mineral supplement tablets market is expected to witness high growth, exhibiting a CAGR of 4.7% over the forecast period, due to increasing prevalence of lifestyle diseases such as diabetes, cardiovascular disorders and obesity.

Regional analysis
North America dominates the global vitamin and mineral supplement tablets market due to rising health awareness and high disposable income in countries like the US and Canada. Additionally, the Asia Pacific region is expected to exhibit the fastest growth over the forecast period owing to growing geriatric population, increasing lifestyle diseases and rising healthcare expenditure in the region.

Key players
Key players operating in the vitamin and mineral supplement tablets market are Otsuka Pharmaceutical Co., Ltd., NutraScience Labs, Glanbia plc, Herbalife Nutrition, Abbott, Amway, Bayer AG, GlaxoSmithKline plc, NSE, inc. Company, Bactolac Pharmaceutical, Inc., Nature's Way Products, LLC, Noreva Biotech, Pharmavite, Brunel Healthcare, HTC Health. Otsuka Pharmaceutical Co., Ltd. and Abbott hold a significant share in the global market due to their diverse product portfolio and strong distribution network across countries.

Onychomycosis Treatment Market 2023 Report Contains Key Vendor Analysis, Vendor Landscape and Forecast to 2030

 

The global Onychomycosis Treatment Market is estimated to be valued at US$ 3.22 Bn in 2023 and is expected to exhibit a CAGR of 6.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Onychomycosis, also known as fungal nail infection, is a common fungal infection of the nail bed and surrounding tissue. It is caused by different types of fungi and affects 10% to 18% of the population. Topical drugs, oral drugs, and laser therapy are commonly used treatment options for this infection. They provide relief from nail discoloration, thickness and detachment associated with fungal nail infection.

Market key trends:
Topical drugs segment is witnessing high growth due to rising preference for these drugs over oral drugs. Some of the key benefits of topical drugs include convenient topical application, lesser risk of systemic drug reactions, and targeted local treatment. For example, efinaconazole topical solution 10% (Jublia) was approved by FDA in 2014 and has shown clinical cure rate of 35% to 45% in clinical trials. This increasing adoption of topical drugs over oral drugs is one of the major trends fueling growth of the onychomycosis treatment market.
Segment Analysis

The global onychomycosis treatment market is segmented into infection type, treatment type, route of administration, distribution channel, and end user. Based on infection type, the market is segmented into distal subungual onychomycosis, white superficial onychomycosis, proximal subungual onychomycosis and candidal onychomycosis. Among these, the distal subungual onychomycosis segment dominates the market due to the high prevalence of infection in toe nails. Based on treatment type, the market is segmented into drugs and lasers. The drugs segment holds largest market share due to wide availability and adoption of oral antifungal drugs for onychomycosis treatment.

Key Takeaways

The global onychomycosis treatment market is expected to witness high growth, exhibiting CAGR of 6.1% over the forecast period, due to increasing prevalence of nail fungal infections worldwide.

Regional analysis - North America dominates the global market holding maximum market share of over 35.0% in 2023 owing to developed healthcare infrastructure and technological advancements in treatment options. Asia Pacific is expected to exhibit fastest growth during the forecast period due to increasing awareness about nail fungal infections and availability of effective treatment options.

Key players - Key players operating in the onychomycosis treatment market are Lumenis Ltd., Cipla Ltd., Bayer AG, Johnson & Johnson, Moberg Pharma AB, Pfizer Inc., Novartis, Galderma SA, Dr. Reddys Laboratories Ltd., Medimetriks Pharmaceuticals Inc., and Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.), among others. These players are focusing on new product launches, mergers, acquisitions and collaborations to strengthen their market presence.

Memory Enhancement Drugs Market Prediction by 2023 – Worldwide Top Players Analysis, Demand and Trends in 2030

 

The global Memory Enhancement Drugs Market is estimated to be valued at US$ 8.6 Bn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2028 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Memory enhancement drugs help improve memory, concentration, and other cognitive functions. These prescription drugs are used treat conditions like Alzheimer’s disease, depression, and attention deficit hyperactivity disorder (ADHD). Some popular classes of memory drugs include acetylcholinesterase inhibitors and NMDA receptor antagonists.

Market key trends:
One of the major trends in the memory enhancement drugs market is the increasing adoption of nootropics. Nootropics, also known as smart drugs, are substances that improve cognitive functions such as memory, creativity, motivation, and concentration. Especially, young professionals in their 20s and 30s are increasingly consuming over-the-counter nootropics known as neuroenhancers to boost their memory, attention, and problem-solving abilities. The global neuroenhancer market is projected to grow at a CAGR of 6.5% during the forecast period. Growing culture of performance enhancement and demand for functional brain health are some of the key factors driving the demand for nootropics.
Segment Analysis

The global memory enhancement drugs market is segmented on the basis of product type, indication, and distribution channel. Based on product type, the market is bifurcated into prescription drugs and OTC drugs. The prescription drugs segment currently dominates the market owing to the high prescription rates of memory enhancement medications for indications such as Alzheimer's disease and other forms of dementia.

Key Takeaways

The global memory enhancement drugs market size is expected to witness high growth, exhibiting a CAGR of 5.6% over the forecast period, due to the increasing prevalence of neurological disorders such as Alzheimer's disease and dementia.

Regional Analysis

North America currently dominates the memory enhancement drugs market accounting for over 40% of the global market share in 2023. The region is expected to continue dominating over the forecast period due to advanced healthcare infrastructure and increasing adoption of innovative drugs and therapies for memory enhancement.

Key Players

Key players operating in the memory enhancement drugs market are Pfizer Inc., UCB S.A., Takeda Pharmaceutical Company, Shire plc., Sanochemia Pharmazeutika AG, Allergan plc., Novartis AG, Alkem Laboratories Ltd., Paradigm Healthcare, Intas Pharmaceutical Ltd., Taurus Laboratories Pvt. Ltd. Pfizer Inc. currently leads the market with its market-leading drugs such as Xeljanz and Aricept indicated for improving memory and cognition.

Chronic Aspergillosis Treatment Market Checkout the Unexpected Future

 

The global Chronic Aspergillosis Treatment Market is estimated to be valued at US$ 3.21 Bn in 2023 and is expected to exhibit a CAGR of 5.0% over the forecast period 2024 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Chronic aspergillosis treatment products are used to treat chronic pulmonary aspergillosis infections. These include antifungal drugs such as voriconazole and itraconazole which inhibit fungal growth. Chronic aspergillosis often develops in people with pre-existing lung diseases and requires long term management.

Market key trends:
One of the key trends in the chronic aspergillosis treatment market is the rising number of clinical trials for novel products. For instance, Pulmocide Ltd. is developing inhaled antifungalvoriconazole (POB-101) for the treatment of severe asthmatic patients with allergic bronchopulmonary aspergillosis (ABPA). Inhaled drugs ensure direct delivery of antifungals to the site of infection in the lungs and are more effective compared to oral drugs. They also help reduce systemic side effects. This novel drug delivery approach is expected to boost the growth of the chronic aspergillosis treatment market during the forecast period.
Segment Analysis
The chronic aspergillosis treatment market is segmented into type and drugs. Based on type, the market is segmented into allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), chronic sino-pulmonary aspergillosis, and chronic cutaneous aspergillosis. The ABPA segment dominates the market as it is the most common form of chronic aspergillosis. Symptoms like shortness of breath, coughing, fever etc. are caused due to ABPA, making it a dominating segment.

Key Takeaways
The global chronic aspergillosis treatment market is expected to witness high growth, exhibiting CAGR of 5.0% over the forecast period, due to increasing prevalence of chronic aspergillosis diseases across the world.

Regional analysis
North America is expected to dominate the global chronic aspergillosis treatment market owing to increasing approval for novel drugs and developed healthcare infrastructure in the region. Europe is expected to be the second largest market due to presence of key players focusing on R&D activities for developing advanced therapies.

Key players
Key players operating in the chronic aspergillosis treatment market are Astellas Pharma Inc., Abbott Laboratories, Pfizer Inc., Pulmocide Ltd., Johnson & Johnson, Mylan N.V., Glenmark Pharmaceuticals, Merck & Co., Inc., Mayne Pharma Group Limited, GlaxoSmithKline plc., PULMATRiX, Inc., F2G Ltd, Teva Pharmaceutical Industries Ltd., and Novartis International AG.

The Ontogenetic Market is Estimated To Witness High Growth Owing To Increasing Funding For Neuroscience Research

 

The global Ontogenetic Market is estimated to be valued at US$ 567.3 Mn in 2023 and is expected to exhibit a CAGR of 4.2% over the forecast period 2028 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Ontogenetic products are used for observing development process of organisms and cell populations. They offer non-invasive and real time details about structural changes and gene expressions during growth and maturation phases.

Market key trends:
Development of advanced microscopy techniques is one of the major trends driving the ontogenetic market growth. Technological advancements like multiphoton microscopy, super resolution microscopy and light sheet fluorescence microscopy enable high resolution 3D and 4D ontogenetic imaging. They provide structural and functional details with high sensitivity and specificity. Growing applications of these advanced microscopy techniques in developmental biology, neuroscience and genetics are augmenting the demand of ontogenetic market.
Segment Analysis
The ontogenetic market can be segmented based on product, application and end-user. Based on product, the ontogenetic market can be categorized into laser, lamps, LED lights and others. The laser segment dominated the global market in 2022 owing to widespread adoption of lasers for various biomedical applications such as ophthalmology, dermatology and others. However, the LED lights segment is expected to grow at the fastest CAGR owing to benefits such as compact size, low power consumption and longer operational life of LED lights.

Key Takeaways
The global ontogenetic market size was valued at US$ 567.3 Mn in 2023 and is expected to witness high growth, exhibiting a CAGR of 4.2% over the forecast period. Growth of the market is attributed to increasing demand for non-invasive and minimally invasive aesthetic procedures.

Regional analysis indicates that North America dominates the ontogenetic market currently owing to significant adoption of advanced aesthetic technologies and presence of major market players in the region. However, Asia Pacific is anticipated to grow at the fastest rate during the forecast period. Factors such as rising medical tourism in countries such as India, China and South Korea along with increasing awareness about aesthetic treatments are expected to fuel the market growth.

Key players operating in the ontogenetic market include Coherent Inc., Thorlabs Inc., Bruker Corporation, Laserglow Technologies, GenSight Biologics S.A, Hubner group (Cobolt Inc.), Judges Scientific Plc (Scientifica), Noldus Information Technology, and Shanghai Laser & Optics Century Co. Ltd. Major players are focusing on new product launches, expansion of manufacturing facilities and acquisitions for strengthening their market position. For instance, in 2022, Thorlabs Inc. acquired Optics Balzers AG to enhance its optics manufacturing capabilities.

Disease-Modifying Antirheumatic Drug Market Based On, Industry News, Gross Margin 2030

 

The global Disease-Modifying Antirheumatic Drug (DMARD) Market is estimated to be valued at US$ 21.42 Bn in 2023 and is expected to exhibit a CAGR of 3.6% over the forecast period 2028 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Disease-Modifying Antirheumatic Drugs (DMARDs) are a class of drugs that are used to help slow the progression of autoimmune diseases such as rheumatoid arthritis and psoriatic arthritis. DMARDs work by modifying or controlling the disease process and help prevent further joint damage. These drugs suppress the immune system and reduce symptoms like pain, swelling and stiffness.

Market key trends:
One of the key trends in the DMARD market is increased research for newer generation DMARDs for treating psoriatic arthritis. Psoriatic arthritis is a chronic inflammatory disease associated with psoriasis. According to estimations by the National Psoriasis Foundation, around 30% of people with psoriasis may develop psoriatic arthritis. Currently available DMARDs are unable to provide long term relief for psoriatic arthritis symptoms. Drug manufacturers are investing in research and clinical trials for newer targeted DMARDs with novel mechanisms of action for better management of psoriatic arthritis.
Segment Analysis
The global disease-modifying antirheumatic drug (DMARD) market is segmented into origin, route of administration, drug class, indication, end user, and distribution channel. Based on origin, the market is bifurcated into biological and non-biological DMARDs. The non-biological DMARDs segment currently dominates the market due to their affordable costs and ease of availability. However, the biological DMARDs segment is expected to witness higher growth during the forecast period owing to the better efficacy of these drugs over non-biological ones.

Key Takeaways
The global disease-modifying antirheumatic drug (DMARD) market size was valued at US$ 21.42 billion in 2023. It is expected to grow at a substantial CAGR of 3.6% during the forecast period. The growth is being driven by the increasing prevalence of rheumatoid arthritis and other autoimmune disorders across the world.

Regional analysis: North America dominates the global DMARD market currently due to advanced healthcare facilities and high treatment rates in the region. It is followed by Europe. However, Asia Pacific is expected to witness the highest growth over 2028-2030 owing to increasing healthcare investments, rising awareness regarding autoimmune conditions, and growing penetration of key market players in countries such as China and India.

Key players: Key players operating in the DMARD market include Sanofi., Pfizer, F. Hoffman-La Roche AG, Johnson & Johnson, AbbVie Inc., Eli Lilly & Company, Amgen Inc., Swedish Orphan Biovitrum AB, Bristol-Myers Squibb Company, UCB S.A., Gilead Sciences, Inc., and Cumberland Pharmaceuticals Inc. These companies collectively account for a significant portion of the overall market revenue. Sanofi. leads the market with strong product offerings across drug classes.

Telerehabilitation Systems Market is Estimated To Witness High Growth Owing To Rising Adoption of Virtual and Remote Care.

 

The global Telerehabilitation Systems Market is estimated to be valued at US$ 254.6 Mn in 2023 and is expected to exhibit a CAGR of 14% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Telerehabilitation systems utilize technology like Virtual Reality for remote delivery of rehabilitation services like physical, occupational and speech therapy. This has enabled access to therapy from home which has boosted the demand for telerehabilitation amidst mobility restrictions during the pandemic.

Market key trends:
One of the major trends driving the telerehabilitation market is the rising geriatric population with limited mobility. Virtual physical therapy solutions help the elderly receive rehabilitation services remotely from the comfort of their homes. The convenience and flexibility offered by telerehabilitation is boosting its adoption across various healthcare settings. Furthermore, growth in telehealth and digital health investments is also fueling innovations in telerehabilitation systems with features like interactive sessions and gamified therapy programs.

Segment Analysis
The telerehabilitation systems market is segmented by application into stroke, traumatic brain injury, Parkinson's disease, multiple sclerosis, low back pain, and other applications. Among all, the stroke segment dominates the market and accounted for the largest market share in 2023. Stroke patients need timely rehabilitation or physical therapy sessions to improve mobility and function. Telerehabilitation aids stroke patients to continue their therapy from home and achieve better therapeutic outcomes.

Key Takeaways
The global telerehabilitation systems market is expected to witness high growth, exhibiting a CAGR of 14% over the forecast period, due to increasing geriatric population and rising chronic diseases.

Regional analysis
North America dominates the telerehabilitation systems market and is expected to continue its dominance over the forecast period. This is attributed to growing adoption of remote patient monitoring and telerehabilitation solutions across healthcare settings in the US andCanada. Asia Pacific is expected to exhibit the fastest growth over the forecast period owing to expanding healthcare infrastructure and increasing geriatric population in major Asian countries, especially China and India.

Key players
Key players operating in the telerehabilitation systems market size are Reflexion Health, Inc., 270 Vision Ltd., CoRehab srl, Hinge Health, SWORD Health, MIRA Rehab Limited, Flex, Neuro Rehab VR, Evolv Rehabilitation Technologies SL, Yancheng Tianrun Medical Technology Co., Ltd, Tyromotion Gmbh, Brontes Processing Ltd., Bridgeway Senior Healthcare, Rehametrics, Geminus-Qhom, MindMaze, DIH Medical, and Doctor Kinetics. These companies continuously focus on new product launches and mergers & acquisitions to strengthen their market position and expand their presence in various regions.

Telehealth is fastest growing segment fueling the growth of Digital Breast Tomosynthesis Equipment Market

 

The global Digital Breast Tomosynthesis Equipment Market is estimated to be valued at US$ 2,400.6 Mn or Million in 2023 and is expected to exhibit a CAGR of 15. % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Digital breast tomosynthesis equipment provides three-dimensional (3D) images of breast that helps doctors to accurately diagnose breast cancer. It is a revolutionizing technology that produces multiple X-ray breast images from different angles and uses computer algorithms to reconstruct them into 3D images. This improves detection of cancer and reduces chances of false positive results.

Market key trends:
One of the key trends in the digital breast tomosynthesis equipment market is replacement demand from upgraded technologies. Regular replacement of obsolete tomosynthesis equipment with newer breast cancer screening technologies leads to repeat sales and upgrades. While conventional 2D mammography systems have been standard for decades, new tomosynthesis models offer improved accuracy. This drives the need for replacement and upgrade of legacy 2D systems with advanced breast tomosynthesis solutions.


Segment Analysis:
The global digital breast tomosynthesis equipment market is segmented by product into standalone and integrated. The integrated segment dominated the market in 2022 and is expected to continue its dominance over the forecast period. Integrated digital breast tomosynthesis equipment offers benefits such as lower cost of ownership and ease of use as compared to standalone equipment.

Key Takeaways:
The global digital breast tomosynthesis equipment market is expected to witness high growth, exhibiting a CAGR of 15% over the forecast period, due to increasing incidence of breast cancer and growing awareness regarding early detection.

Regional analysis:
North America dominated the global market in 2022 and is expected to continue its dominance over the forecast period. High awareness regarding breast cancer screening and availability of favorable reimbursement policies in the region is driving the growth of the market.

Key players:
Major players operating in the global digital breast tomosynthesis equipment market size include Hologic, Inc., Internazionale Medico Scientifica-S.R.L, GE Healthcare, Siemens Healthineers, Fujifilm Corporation, Planmed OY, Trivitron Healthcare, Varex Imaging Corporation, and Analogic Corporation.

The global digital breast tomosynthesis equipment market size was valued at US$ 2,400.6 Mn in 2023 and is expected to reach over US$ 6,800 Mn by 2030, expanding at a CAGR of 15% during the forecast period.

Genetic Therapies is fastest growing segment fueling the growth of Parkinson's Disease Therapeutic Market

 

The global Parkinson's Disease Therapeutic Market is estimated to be valued at US$ 5.11 Bn or billion in 2023 and is expected to exhibit a CAGR of 6.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Parkinson's disease is a progressive nervous system disorder that affects movement. It occurs when dopamine-producing neurons in the brain die or become impaired. The market products include Carbidopa/Levodopa, Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics and other drugs that help control symptoms but don't slow, stop or reverse progression of the disease.

Market key trends:
One of the major trend in the Parkinson's disease therapeutic market is the growing emphasis on research and development activities to develop novel therapies for neurodegenerative conditions like Parkinson's disease. Pharmaceutical companies and research institutes are investing heavily in R&D to develop advanced therapies such as gene therapies, stem cell therapies, and disease-modifying therapies. For instance, companies like Voyager Therapeutics and Denali Therapeutics are developing novel gene therapies for Parkinson's disease using viral vectors to deliver genes to the brain cells. These advanced therapies hold promise to slow or stop progression of neurodegeneration in Parkinson's disease.
Segment Analysis
The global Parkinson's disease therapeutic market is segmented based on drug class, distribution channel and region. Based on drug class, the market is segmented into levodopa/carbidopa, dopamine receptor agonists, MAO-B inhibitors, anticholinergics, COMT inhibitors and others. Among these, levodopa/carbidopa occupies the largest market share as it is the most effective medication for controlling motor symptoms of Parkinson's disease. Based on distribution channel, the market is divided into hospital pharmacies, retail pharmacies and online pharmacies. Hospital pharmacies dominate the market due to the availability of wide range of Parkinson's disease therapeutics and physicians recommendation for critical patients.

Key Takeaways
The global Parkinson's disease therapeutic market is expected to witness high growth, exhibiting CAGR of 6.1% over the forecast period, due to increasing prevalence of Parkinson's disease.

Regional analysis:
North America holds the largest share in the global Parkinson's disease therapeutic market due to availability of advanced healthcare facilities and presence of key market players in the region. Asia Pacific is expected to witness the fastest growth rate during the forecast period owing to rising awareness regarding Parkinson's disease and increasing healthcare expenditure in emerging economies like India and China.

Key players:
Key players operating in the Parkinson's disease therapeutic market size are Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline Plc., AbbVie Inc., Merck & Co., Inc., Zydus Cadila, Dr. Reddyâ€TMs Laboratories, Sun Pharmaceutical Industries Ltd., Cipla Inc., Boehringer Ingelheim International GmbH, Denali Therapeutics Inc., Biogen Inc., Prevail Therapeutics, Eli Lilly and Company and Voyager Therapeutics.

Laser Therapy is Fastest Growing Segment Fueling Growth of Hair Loss Treatment Market

 

The global Hair Loss Treatment Market is estimated to be valued at US$ 4.24 Bn in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Hair loss treatments help in slowing down the hair fall and enhancing hair regrowth. Various products available for hair loss treatment include shampoos, serums, lasers, medications, supplements etc. that nourish the scalp and strengthen hair follicles promoting hair growth.

Market Key trends:
Laser therapy has emerged as one of the most effective and fastest growing hair loss treatment segment. It involves use of low-level laser therapy comb or helmet for stimulating hair follicles and improving blood circulation in scalp. This non-invasive procedure has minimal to no side effects. Some other key trends include growing demand for herbal supplements and natural ingredients based hair loss treatments, preference for non-surgical and non-medical treatment options, and rising availability of at-home hair loss treatments kits.
Segment Analysis
The hair loss treatment market can be segmented into product type, mode of prescription, gender, and end-users. Based on product type, minoxidil products dominate the market owing to the effectiveness and higher acceptance of topical solutions in both males and females. Further, the minoxidil segment is anticipated to continue dominating the overall hair loss treatment market over the forecast period.

Key Takeaways
The global hair loss treatment market is expected to witness high growth, exhibiting CAGR of 6.2% over the forecast period, due to increasing product innovations and growing awareness regarding hair loss treatment options.

The global hair loss treatment market size is expected to reach US$ 4.24 Bn in 2023.

North America dominates the global hair loss treatment market owing to the high awareness levels regarding hair loss problems and easy availability of treatment options in the region. However, Asia Pacific is likely to witness the fastest growth over the forecast period due to growing disposable incomes and increasing inclination towards aesthetics.

Key players operating in the hair loss treatment market growth are Viviscal, Cipla Inc., Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Reddyâ€TMs Laboratories, Ranbaxy Laboratories Ltd., HCell Inc., Follica, Inc., Aurobindo Pharma, and Zydus Lifesciences Inc. Key players are focusing on new product launches and expansion strategies to strengthen their position in the global market.